A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

NCT02974725 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

241

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Non-Small Cell Lung Cancer
Melanoma

Interventions

DRUG: LXH254
DRUG: LTT462
DRUG: Trametinib
DRUG: Ribociclib

Sponsor

Novartis Pharmaceuticals